# Omalizumab Weight-Based Dosing Efficacy Trial

> **NCT06943534** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Allergies
- Food Allergy

## Interventions

- **DRUG:** 5mg/kg omalizumab injection
- **DRUG:** 15mg/kg omalizumab injection

## Key facts

- **NCT ID:** NCT06943534
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943534, "Omalizumab Weight-Based Dosing Efficacy Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06943534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*